Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: an F-MISO PET/CT study

Joanna C. Porter[1,11], Thida Win[2,11], Kjell Erlandsson[3], Francesco Fraioli[3], Alaleh Rashidnasab[3], Beverley Holman[3], Balaji Ganeshan[3], Nicholas J. Screaton[4], Toby M. Maher[5,6,7], Raymond Endozo[3], John Hoath[3], Robert I. Shortman[3], Elise Emond[3], Kris Thielemans[3], Brian F. Hutton[3], Pauline T. Lukey[8], Franklin Aigbirhio[9], Saif Khan[10], Manuel Rodriguez-Justo[10] and Ashley M. Groves[3]

[1]CITR, UCL and Interstitial Lung Disease Centre, UCLH, London, UK. [2]Respiratory Medicine, Lister Hospital, Stevenage, UK. [3]Institute of Nuclear Medicine, UCL/H, London, UK. [4]Radiology Dept, Papworth Hospital, Papworth Everard, UK. [5]Hastings Centre for Pulmonary Research and Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. [6]Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College, London, UK. [7]National Institute for Health Research (NIHR) Respiratory Biomedical Research Unit, Royal Brompton Hospital, London, UK. [8]Target to Treatment Consulting Ltd, Stevenage Bioscience Catalyst, Stevenage, UK. [9]Wolfson Brain Imaging Centre, University Cambridge, Cambridge, UK. [10]Dept of Histopathology, UCLH, London, UK. [11]Joint first authors.

Ashley Groves (ashleygroves@nhs.net)

Shareable abstract (@ERSpublications)
This study found no detectable ^{18}F-MISO signal in fibrotic lung despite some histological expression of hypoxic markers, and concludes that in these IPF patients, the degree of hypoxia is too low to be detectable with ^{18}F-MISO-PET/CT https://bit.ly/3wLJwja

Cite this article as: Porter JC, Win T, Erlandsson K, *et al*. Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: an F-MISO PET/CT study. *Eur Respir J* 2021; 58: 2004584 [DOI: 10.1183/13993003.04584-2020].

Received: 5 Jan 2021
Accepted: 4 June 2021

To the Editor:

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing lung disease, with an incidence of ~1 per 10 000 per year, and a poor prognosis with limited treatments [1]. The role of hypoxia in disease progression is unclear.